BR0312474A - Partìcula viral adjuvante - Google Patents

Partìcula viral adjuvante

Info

Publication number
BR0312474A
BR0312474A BR0312474-6A BR0312474A BR0312474A BR 0312474 A BR0312474 A BR 0312474A BR 0312474 A BR0312474 A BR 0312474A BR 0312474 A BR0312474 A BR 0312474A
Authority
BR
Brazil
Prior art keywords
vlp
protein
viral particle
immunogen
particle
Prior art date
Application number
BR0312474-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Leclerc
Nathalie Majeau
Philippe Tessier
Constantino Rober Lopez-Macias
Original Assignee
Denis Leclerc
Nathalie Majeau
Philippe Tessier
Constantino Rober Lopez-Macias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denis Leclerc, Nathalie Majeau, Philippe Tessier, Constantino Rober Lopez-Macias filed Critical Denis Leclerc
Publication of BR0312474A publication Critical patent/BR0312474A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR0312474-6A 2002-07-05 2003-06-30 Partìcula viral adjuvante BR0312474A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39365902P 2002-07-05 2002-07-05
PCT/CA2003/000985 WO2004004761A2 (en) 2002-07-05 2003-06-30 Adjuvant viral particle

Publications (1)

Publication Number Publication Date
BR0312474A true BR0312474A (pt) 2005-04-26

Family

ID=30115621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312474-6A BR0312474A (pt) 2002-07-05 2003-06-30 Partìcula viral adjuvante

Country Status (14)

Country Link
US (2) US7641896B2 (enExample)
EP (2) EP2272525A3 (enExample)
JP (1) JP4953570B2 (enExample)
KR (1) KR20050044886A (enExample)
CN (1) CN1665528B (enExample)
AU (1) AU2003281246A1 (enExample)
BR (1) BR0312474A (enExample)
CA (1) CA2434000C (enExample)
DK (1) DK1523329T3 (enExample)
ES (1) ES2431963T3 (enExample)
MX (1) MXPA05000287A (enExample)
NO (1) NO20050396L (enExample)
PT (1) PT1523329E (enExample)
WO (1) WO2004004761A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2434000C (en) * 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle
AU2005286475A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
WO2006045796A2 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
KR100688522B1 (ko) * 2005-01-18 2007-03-02 삼성전자주식회사 영상데이터 압축기 및 압축방법
KR20080018176A (ko) * 2005-06-01 2008-02-27 다우 글로벌 테크놀로지스 인크. 다가 바이러스 유사 입자 생산 방법
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CA2669485C (en) * 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
WO2012048430A1 (en) * 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
WO2008058369A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
CA2676481A1 (en) * 2007-01-26 2008-07-31 Folia Biotech Inc. Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
JP2010524508A (ja) * 2007-04-27 2010-07-22 ダウ グローバル テクノロジーズ インコーポレイティド 可溶性組換え二十面体ウイルス様粒子の生産及びインビボ組織化の改善
WO2009033276A1 (en) * 2007-09-11 2009-03-19 UNIVERSITé LAVAL Malva mosaic virus and virus-like particles and uses thereof
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
US20130236491A1 (en) * 2010-12-09 2013-09-12 Iosif Grigorievich Atabekov Spherical nano and microparticles derived from plant viruses for the display of foreign proteins or epitopes
DK2707480T3 (da) 2011-05-13 2017-11-13 Folia Biotech Inc Viruslignende partikler og fremgangsmåde til fremstilling heraf
EP2717910B1 (en) 2011-06-09 2019-01-23 Biomay Ag Peptide carrier fusion proteins as allergy vaccines
HK1203983A1 (en) * 2012-04-02 2015-11-06 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
US20160228541A1 (en) * 2013-09-19 2016-08-11 Alain Lamarre Papaya mosaic virus and virus-like particles in cancer therapy
US20180153984A1 (en) * 2015-04-30 2018-06-07 The Regents Of The University Of California Adjuvant particles comprising adenosine receptor antagonists
CA3176880A1 (en) * 2020-03-31 2021-10-07 Mediphage Bioceuticals, Inc. Vectors for producing virus-like particles and uses thereof
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79880A0 (en) 1985-08-29 1986-11-30 Inst Medical W & E Hall Recombinant virus
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
CA2202761A1 (en) 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
GB9607899D0 (en) 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
CA2288129A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19752855C2 (de) * 1997-11-28 2003-04-03 Bundesrepublik Deutschland Let Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
AU5122499A (en) 1998-07-27 2000-02-21 Genentech Inc. Improved transformation efficiency in phage display through modification of a coat protein
FR2786773B1 (fr) 1998-12-03 2002-03-08 Univ Paris Curie Proteines d'enveloppe, methodes et utilisations
AU770225B2 (en) * 1998-12-04 2004-02-19 Biogen Idec Ma Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
GB9924352D0 (en) 1999-10-14 1999-12-15 Hellendoorn Koen Methods,compositions and applications relating to the generation of novel plant viral particles
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
AUPQ661600A0 (en) 2000-03-31 2000-05-04 Macfarlane Burnet Centre For Medical Research Limited, The A nucleic acid construct and methods related thereto
IT1317046B1 (it) * 2000-06-16 2003-05-26 Ist Superiore Sanita Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni
WO2002000169A2 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
DE60137230D1 (de) 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0028319D0 (en) * 2000-11-20 2001-01-03 Univ Southampton Materials and methods relating to fusion proteins for inducing an immune response
ITRM20010332A1 (it) * 2001-06-11 2002-12-11 Ist Superiore Sanita Vaccini a subunita' e procedimenti per la loro produzione.
US8101189B2 (en) * 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2434000C (en) * 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle

Also Published As

Publication number Publication date
NO20050396L (no) 2005-01-25
ES2431963T3 (es) 2013-11-28
WO2004004761A3 (en) 2004-05-06
DK1523329T3 (da) 2013-10-14
EP2272525A3 (en) 2011-11-16
CN1665528A (zh) 2005-09-07
HK1075214A1 (en) 2005-12-09
WO2004004761A2 (en) 2004-01-15
US8282940B2 (en) 2012-10-09
CA2434000C (en) 2012-07-17
MXPA05000287A (es) 2005-09-08
US20050048082A1 (en) 2005-03-03
JP4953570B2 (ja) 2012-06-13
EP2272525A2 (en) 2011-01-12
PT1523329E (pt) 2013-10-08
CN1665528B (zh) 2013-05-15
KR20050044886A (ko) 2005-05-13
AU2003281246A1 (en) 2004-01-23
US7641896B2 (en) 2010-01-05
EP1523329A2 (en) 2005-04-20
EP1523329B1 (en) 2013-07-24
JP2006504644A (ja) 2006-02-09
CA2434000A1 (en) 2004-01-05
US20090280145A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
BR0312474A (pt) Partìcula viral adjuvante
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
DK1185660T3 (da) Svinecircovirus-vaccine i rekombinant poxvirus
ECSP045300A (es) Antígenos virales
BR9814487A (pt) "vacina"
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
BRPI0407877A (pt) conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
EP1644037A4 (en) FUNCTIONAL INFLUENZA-VIRUS-SIMILAR PARTICLES (VLPS)
MY134424A (en) Stable influenza virus preparations with low or no amount of thiomersal
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
WO2021202599A3 (en) Adeno-associated virus based compositions and related methods for inducing humoral immunity
ATE267256T1 (de) Hepatis e-virus antigene und dessen verwendungen
BR0112020A (pt) Partìculas tipo vìrus de bvdv
BR112022001070A2 (pt) Composição de imunogenicidade polivalente para papilomavírus humano
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired